Coya Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5850 San Felipe St Ste 500, Houston, Tex...Phone Number
(800) 587-8170Website
www.coyatherapeutics.comRevenue
$7.9 MillionStock Symbol
COYAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Coya Therapeutics
Coya Therapeutics develops immune based treatments aimed at slowing and modifying serious neurodegenerative and autoimmune conditions. Its teams advance regulatory T cell and related therapies from discovery through clinical development, working to bring new options to patients with high unmet medical needs.Explore more
Coya Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Coya Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Coya Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Coya Therapeutics launches new products
Click to see if Coya Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Coya Therapeutics
Check out if Coya Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Coya Therapeutics has new funding data
Coya Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Coya Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Coya Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Coya Therapeutics
Compare insights from companies similar to Coya Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Coya Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Coya Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Coya Therapeutics.
Coya Therapeutics financials insights
Gather financial insights about Coya Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$10M
2022
Unspecified
$10.3M
2024
Share Placement
$5M
2026
Stock/Share Issuance
$11.1M
Coya Therapeutics Tech Stack
A closer look at the technologies used by Coya Therapeutics
Most Recent Scoops
Partnership
Coya Therapeutics has entered into a strategic partnership with Dr. Reddy's Laboratories, in which Dr. Reddy's acquired the commercial rights for ALS in major global markets excluding Japan and Latin America, with Coya Therapeutics eligible to receive mid-teen royalties and up to $650 million in sales milestones upon commercialization.
Partnership
Project
anticipates completing enrollment for the ALSTARS trial in H2 2026, with top-line data readout expected in Q1 2027, and also plans to initiate a Phase IIa study in patients with frontotemporal dementia in H2 2026.
Clinical Operations
Project
Coya Therapeutics is advancing a preclinical program, COYA 303, which combines low-dose interleukin-2 with a GLP-1 agonist, with in vitro and inflammatory rodent model studies demonstrating potential synergistic effects in reducing neuroinflammatory markers.
Medical Research
Project
Coya Therapeutics has received FDA acceptance of an IND to advance Coya 302 into a Phase 2 study in frontotemporal dementia, targeting approximately 60 patients in a controlled blinded study focused on the nonfluent variant of FTD, with trial initiation expected in the second half of this year.
Pharmaceuticals, Clinical Operations
Partnership
Partnership
Coya Therapeutics News & Media
Coya Therapeutics raises $11M to advance ALS drug development - InnovationMap
Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.Coya Therapeutics hopes for ALS Treg approval on Phase II trial
Coya’s lead asset, COYA 302, has previously demonstrated disease-modifying activity and is now in Phase II.2025 Houston Innovation Awards finalists: Scaleup of the Year - InnovationMap
From raising funding rounds to earning FDA acceptance, some of Houston's most innovative companies reached major milestones this year. Six of the fastest-growing companies in Houston are finalists for 2025 Scaleup of the Year.CORE Public Relations Wins Platinum Pinnacle Awards for Healthcare and Technology PR Campaigns
GARDEN CITY, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- CORE Public Relations (CORE PR), a full-service, integrated public relations agency and a division of CORE IR, today announced it has been named the recipient of two 2025 Platinum Pinnacle Awards for Healthcare and Technology PR Campaigns for client companies Coya Therapeutics and Richtech Robotics, respectively.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Coya Therapeutics
Sign Up For FreeTo access detailed company insights
Coya Therapeutics develops immune based treatments aimed at slowing and modifying serious neurodegenerative and autoimmune conditions. Its teams advance regulatory T cell and related therapies from discovery through clinical development, working to bring new options to patients with high unmet medical needs.... Read More
